Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2012; 02(01): 9-11
DOI: 10.4103/2231-0770.94804
CASE REPORT

Nephrotic syndrome after treatment of Crohn′s disease with mesalamine: Case report and literature review

Belal M Firwana
Elmhurst Hospital Center, Mount Sinai School of Medicine, Elmhurst, NY, USA; Department of Internal Medicine, University of Missouri, Columbia, MO, USA
,
Rim Hasan
Elmhurst Hospital Center, Mount Sinai School of Medicine, Elmhurst, NY, USA; Department of Internal Medicine, University of Missouri, Columbia, MO, USA
,
Walid Chalhoub
Elmhurst Hospital Center, Mount Sinai School of Medicine, Elmhurst, NY, USA
,
Mazen Ferwana
Department of Internal Medicine, King Saud bin Abdualziz University for Health Sciences, Riyadh, Saudi Arabia
,
Jin-Yong Kang
Department of Gastroenterology, St George′s Hospital, London, UK
,
Joshua Aron
Elmhurst Hospital Center, Mount Sinai School of Medicine, Elmhurst, NY, USA
,
Joseph Lieber
Elmhurst Hospital Center, Mount Sinai School of Medicine, Elmhurst, NY, USA
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Inflammatory bowel disease and its various treatments may affect the kidney in several ways. Recently, case reports have been published documenting the development of nephrotic syndrome after the treatment for inflammatory bowel disease with 5-aminosalicylic acid derivatives. We report a 50-year-old patient who was diagnosed with Crohn′s disease and was treated with mesalamine. The patient subsequently developed nephrotic syndrome and a renal biopsy showed minimal change disease. He was treated with losartan and rosuvastatin and showed improvement in his renal function and serum cholesterol level. This is the first reported case in Crohn′s disease although there have been six previous case reports of nephrotic syndrome following salicylic acid derivatives for ulcerative colitis.

Keywords

Aminosalicylic acid - Crohn′s disease - inflammatory bowel disease - mesalamine - minimal change disease - nephrotic syndrome


Publication History

Article published online:
09 August 2021

© 2012. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Molnar T, Farkas K, Nagy F, Ivanyi B, Wittmann T. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis. Inflamm Bowel Dis 2010;16:552-3.
  • 2 Fofi C, Nicoletti MC, Onetti Muda A, Giulio S. [Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis]. G Ital Nefrol 2003;20:641-4.
  • 3 Skhiri H, Knebelmann B, Martin-Lefevre L, Grunfeld JP. Nephrotic syndrome associated with inflammatory bowel disease treated by mesalazine. Nephron 1998;79:236.
  • 4 Fornaciari G, Maccari S, Borgatti PP, Rustichelli R, Amelio N, Lattuada I, et al. Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis. J Clin Gastroenterol 1997;24:37-9.
  • 5 Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine. BMJ 1990;301:818.
  • 6 Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) 1988;296:1442.
  • 7 Leong J, Fung-Liu B. A case report of nephrotic syndrome due to intake of certolizumab pegol in a patient with Crohn′s disease. Am J Gastroenterol 2010;105:234.